2025
Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease
Lanctôt K, Tumati S, Vieira D, Bawa K, Andreazza A, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Mintzer J, Herrmann N. Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease. Alzheimer's & Dementia 2025, 20: e095596. PMCID: PMC11712725, DOI: 10.1002/alz.095596.Peer-Reviewed Original ResearchTreatment responseBlood-based biomarkersBlood-based biomarkers of neurodegenerationNPI-aClinical predictorsAlzheimer's diseaseClinical predictors of responsePredictive value of biomarkersTumor necrosis factor-alphaOxidative stressNeurofilament lightAffecting treatment responsePredictors of responseNecrosis factor-alphaBiomarkers of neurodegenerationInterleukin (IL)-6Treatment response predictionMonths end pointAssociated with apathyValue of biomarkersNeuropsychiatric Inventory apathy subscalePresence of anxietyPeripheral inflammation
2024
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Alzheimer's & Dementia 2024, 20: e091793. PMCID: PMC11710533, DOI: 10.1002/alz.091793.Peer-Reviewed Original ResearchMini-Mental State ExamBoston Naming TestDigit Span ForwardCategory fluencyWorsening apathyNPI-aCognitive testsAlzheimer's diseaseCognitive change scoresAssociated with cognitive impairmentBaseline cognitive test scoresCognitive test scoresMild to moderate ADAssociated with performanceNaming TestVerbal fluencyExecutive functionMethylphenidate treatmentMethylphenidate groupTrail MakingCognitive domainsCognitive changesMethylphenidatePlacebo-controlled trialNPI-apathy
2023
P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Vieira D, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial. International Psychogeriatrics 2023, 35: 125-126. DOI: 10.1017/s1041610223002557.Peer-Reviewed Original ResearchPotential predictors of treatment outcomePredictors of treatment outcomeResponse to methylphenidateClinically significant apathyAlzheimer's Disease Cooperative Study ActivitiesMedium effect sizeMonths of methylphenidateAlzheimer's diseaseNPI-aMethylphenidate treatmentSignificant apathyApathetic patientsBaseline anxietyAD participantsMethylphenidatePotential predictorsActivities of Daily Living ScaleCompared to placeboNeuropsychiatric symptomsIndex scoreDaily Living ScaleAlzheimer's Disease Cooperative Study Activities of Daily Living ScaleApathyEffect sizeLiving scale
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply